Asheville Gastroenterology Associates, Pa

Asheville, North Carolina 28801

0 studies enrolling now · 43 studies all time

What they study most

Chronic Genotype 1a or 1b HCV Infection, Chronic Hepatitis C, Cirrhosis, Colitis, Ulcerative, Colonic Diseases, Colorectal Cancer, Colorectal Neoplasms, Compensated Cirrhosis, Crohn Disease, Crohn's Disease, Digestive System Diseases, Distal Ulcerative Colitis

Studies at this site

• A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) — Completed
• An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) — Completed
• A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved — Completed
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment — Stopped early
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis — Completed
• A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection — Stopped early
• Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy — Completed
• Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis — Completed
• A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) — Completed
• Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease. — Completed
• BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity — Completed
• The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy — Completed
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
• Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis — Completed
• The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) — Completed
• Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C) — Completed
• Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection — Completed
• Gilead Sustained Virologic Response (SVR) Registry — Completed
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response — Completed
• Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers — Stopped early
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease — Withdrawn before enrolling
• Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis — Completed
• An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1 — Completed
• Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) — Completed
• Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing — Completed
• UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects — Completed
• UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis — Completed
• Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV — Completed
• PRESEPT Study: Evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening — Completed
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease — Completed
• Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) — Completed
• Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection — Completed
• Phase 3 Study of Sofosbuvir and Ribavirin — Completed
• Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection — Completed
• A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C — Completed
• GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype — Stopped early
• Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis — Status unconfirmed
• GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection — Completed
• LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) — Completed
• Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome — Completed
• Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease — Completed